Wattignies, France

Claude Vaccher

This inventor holds 3 USPTO granted patents. Top assignee: Adir Et Compagnie. Active years: 1992-1994.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 3

Forward Citations = 12(Granted Patents)


Company Filing History:


Years Active: 1992-1994

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Claude Vaccher: Innovator in Medicinal Chemistry

Introduction

Claude Vaccher is a notable inventor based in Wattignies, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that target GABAB receptors. With a total of 3 patents to his name, Vaccher's work is recognized for its potential therapeutic applications.

Latest Patents

Vaccher's latest patents include innovative compounds such as 4-amino-3-heteroaryl butyric acid compounds, which are disclosed for their use in treating disorders connected to dysfunctions of GABAB receptors. Another significant patent involves 4-aminobutyric acid compounds, which also target GABAB receptor dysfunctions. These compounds are described in detail, including their chemical formulas and potential medicinal applications.

Career Highlights

Claude Vaccher is associated with Adir Et Compagnie, where he continues to advance his research in medicinal products. His work has been instrumental in developing new therapeutic options for various neurological disorders. Vaccher's dedication to innovation in medicinal chemistry has positioned him as a key figure in his field.

Collaborations

Some of his notable coworkers include Michel Debaert and Pascal Berthelot, who have collaborated with Vaccher on various projects. Their combined expertise has contributed to the successful development of new medicinal compounds.

Conclusion

Claude Vaccher's contributions to medicinal chemistry, particularly in the area of GABAB receptor-targeting compounds, highlight his innovative spirit and commitment to improving healthcare. His work continues to pave the way for new therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…